Jenny Y Y Ooi

List of Publications by Citations

26 papers	1,497 citations	18 h-index	26 g-index
26 ext. papers	1,835 ext. citations	6.5 avg, IF	4.61 L-index

#	Paper	IF	Citations
26	Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. *Archives of Toxicology*, **2015**, 89, 1401-38	5.8	337
25	Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. *Blood*, **2014**, 124, 3829-30	2.2	235
24	miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. *Future Medicinal Chemistry*, **2015**, 7, 1771-92	4.1	132
23	HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes. *Epigenetics*, **2015**, 10, 418-30	5.7	83
22	Vascular histone deacetylation by pharmacological HDAC inhibition. *Genome Research*, **2014**, 24, 1271-84	9.7	64
21	Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. *FASEB Journal*, **2014**, 28, 5097-110	0.9	61
20	The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. *Nature Communications*, **2014**, 5, 5705	17.4	61
19	Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. *PLoS ONE*, **2014**, 9, e90337	3.7	58
18	Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts. *Physiological Reviews*, **2018**, 98, 419-475	47.9	56
17	The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy. *Future Medicinal Chemistry*, **2014**, 6, 205-22	4.1	49
16	Dynamic changes in the cardiac methylome during postnatal development. *FASEB Journal*, **2015**, 29, 1329-43	0.9	47
15	A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. *Bioscience Reports*, **2011**, 31, 333-43	4.1	46
14	The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection. *Advances in Experimental Medicine and Biology*, **2017**, 1000, 187-210	3.6	44
13	Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases. *RNA Biology*, **2017**, 14, 500-513	4.8	38
12	Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload. *Scientific Reports*, **2016**, 6, 22442	4.9	36
11	Investigation into the biological properties of the olive polyphenol, hydroxytyrosol: mechanistic insights by genome-wide mRNA-Seq analysis. *Genes and Nutrition*, **2012**, 7, 343-55	4.3	34
10	Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs. *Journal of Physiology*, **2016**, 594, 5959-5974	3.9	30

9	Lipidomic Profiles of the Heart and Circulation in Response to Exercise versus Cardiac Pathology: A Resource of Potential Biomarkers and Drug Targets. *Cell Reports*, **2018**, 24, 2757-2772	10.6	28
8	MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: potential drug targets?. *Clinical and Experimental Pharmacology and Physiology*, **2014**, 41, 727-37	3	17
7	Distinct lipidomic profiles in models of physiological and pathological cardiac remodeling, and potential therapeutic strategies. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2018**, 1863, 219-234	5	14
6	The yin and yang of adaptive and maladaptive processes in heart failure. *Drug Discovery Today: Therapeutic Strategies*, **2012**, 9, e163-e172		7
5	The Interplay of Protein Coding and Non-Coding RNAs (circRNAs, lncRNAs) During Cardiac Differentiation. *EBioMedicine*, **2017**, 25, 9-10	8.8	5
4	Clusterin is regulated by IGF1-PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity. *Archives of Toxicology*, **2020**, 94, 1763-1768	5.8	4
3	Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player. *Annals of Translational Medicine*, **2016**, 4, 548	3.2	4
2	Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes. *Diabetes*, **2021**, 70, 255-261	0.9	4
1	Translational Potential of Non-coding RNAs for Cardiovascular Disease. *Advances in Experimental Medicine and Biology*, **2020**, 1229, 343-354	3.6	3